Get notified when LSH files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsStanding Risk Factors
- Material Weakness (unchanged) — Company continues to report identical material weaknesses in segregation of duties and written accounting policies with no remediation progress for second consecutive year.
Lakeside exits U.S. freight business, pivots to China pharma; $8.7M loan drives liquidity
Filed May 19, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 15, 2025 · ~2 min read
Key Changes
-
high
Company sold its U.S. freight-forwarding business (ABL Chicago) in Feb 2026 for $1, exiting cross-border logistics entirely to focus solely on pharmaceutical distribution in China—a fundamental strategic pivot.
MD&A: Disposal of ABL Chicago verify on EDGAR → -
high
Pharmaceutical revenue surged 167% quarter-over-quarter to $1.3M, driven by customer expansion (4 to 12 active accounts) and higher infusion product sales; business launched Dec 2024 and now represents 100% of continuing operations.
MD&A: Pharmaceutical Revenue Growth verify on EDGAR → -
high
Company holds $8.7M loan receivable (49% of current assets) from single third party, maturing July 2026; management states ability to fund operations is 'partially dependent' on timely collection, creating material concentration risk.
MD&A: Loan Receivable Concentration verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ADMT 10-K) is open in full — no account needed.
Partner
Trade LSH commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · May 26, 2026 · How we verify